KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Other Accumulated Expenses: 2018-2025

Historic Other Accumulated Expenses for Castle Biosciences (CSTL) over the last 7 years, with Sep 2025 value amounting to $8.9 million.

  • Castle Biosciences' Other Accumulated Expenses rose 10.13% to $8.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.9 million, marking a year-over-year increase of 10.13%. This contributed to the annual value of $8.0 million for FY2024, which is 9.24% up from last year.
  • Castle Biosciences' Other Accumulated Expenses amounted to $8.9 million in Q3 2025, which was up 8.08% from $8.2 million recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Other Accumulated Expenses registered a high of $8.9 million during Q3 2025, and its lowest value of $2.0 million during Q1 2021.
  • Moreover, its 3-year median value for Other Accumulated Expenses was $7.4 million (2024), whereas its average is $7.4 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first spiked by 223.84% in 2022, then dropped by 10.51% in 2023.
  • Castle Biosciences' Other Accumulated Expenses (Quarterly) stood at $5.7 million in 2021, then fell by 7.33% to $5.3 million in 2022, then skyrocketed by 39.05% to $7.3 million in 2023, then climbed by 9.24% to $8.0 million in 2024, then increased by 10.13% to $8.9 million in 2025.
  • Its last three reported values are $8.9 million in Q3 2025, $8.2 million for Q2 2025, and $8.4 million during Q1 2025.